Literature DB >> 23238171

Some transformations of tacrolimus, an immunosuppressive drug.

Dorthe M Skytte1, Jerzy W Jaroszewski1, Kenneth T Johansen1, Steen Honoré Hansen2, Liselotte Hansen3, Peter G Nielsen3, Karla Frydenvang4.   

Abstract

Transformations of the macrocyclic lactone tacrolimus (1), an important immunosuppressive drug produced by Streptomyces species, are described. These transformation products are primarily of interest as reference substances for drug impurity analyses. Upon action of acid (p-toluenesulfonic acid in toluene), tacrolimus is dehydrated by loss of water from the β-hydroxyketone moiety with partial inversion of configuration at C-8, resulting in formation of 5-deoxy-Δ(5,6)-tacrolimus and 5-deoxy-Δ(5,6)-8-epitacrolimus. The structure of the latter was determined by single-crystal X-ray crystallography. The same products are formed upon action of free radicals (iodine in boiling toluene), along with formation of 8-epitacrolimus. The latter is converted by p-toluenesulfonic acid to 5-deoxy-Δ(5,6)-8-epitacrolimus. Treatment of tacrolimus with weak base (1,5-diazabicyclo[4.3.0]nonene) gives, in addition to 8-epitacrolimus, the open-chain acid corresponding to 5-deoxy-Δ(5,6)-tacrolimus, a rare non-cyclic derivative of tacrolimus. Strong base (t-butoxide) causes pronounced degradation of the molecule. Thermolysis of tacrolimus leads to ring expansion by an apparent [3,3]-sigmatropic rearrangement of the allylic ester moiety with subsequent loss of water from the β-hydroxyketone moiety. ¹H and ¹³C NMR spectra of the obtained compounds, complicated by the presence of amide bond rotamers and ketal moiety tautomers, were assigned by extensive use of 2D NMR techniques.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238171     DOI: 10.1016/j.ejps.2012.12.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy.

Authors:  Qi-Jun Wan; Hao-Fei Hu; Yong-Cheng He; Shao-Dong Luan; Hong-Tao Chen; Tong Li; Yi Xu; Hui-Li Xu; Ying Liao
Journal:  Exp Ther Med       Date:  2016-07-14       Impact factor: 2.447

2.  In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates.

Authors:  Yeonseon Lee; Kyung-Tae Lee; Soo Jung Lee; Ji Yoon Beom; Areum Hwangbo; Jin A Jung; Myoung Chong Song; Young Ji Yoo; Sang Hyeon Kang; Anna F Averette; Joseph Heitman; Yeo Joon Yoon; Eunji Cheong; Yong-Sun Bahn
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

3.  Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models.

Authors:  Leslie Rebibo; Connie Tam; Yan Sun; Eve Shoshani; Amit Badihi; Taher Nassar; Simon Benita
Journal:  J Control Release       Date:  2021-03-30       Impact factor: 9.776

4.  Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis.

Authors:  Kexin Sun; Ke Hu
Journal:  Drug Des Devel Ther       Date:  2021-01-12       Impact factor: 4.162

5.  Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis.

Authors:  Yong Zhang; Jun Luo; Bin Hu; Tean Ma
Journal:  J Int Med Res       Date:  2018-06-08       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.